Clinical Trial

Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is to evaluate the efficacy and safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes. The primary objective is to demonstrate equivalence of QLG1091 and Rybelsus. This study is a randomized, open-label, active-controlled, parallel-group, multi-center Study. The total duration of the study will be approximately 33 weeks including screening and follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-17.
Trial Details
NCT Number NCT07487103
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 478 participants
Start Date 2026-05-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-28